Eculizumab: a treatment option for myasthenia gravis?
- PMID: 29066164
- DOI: 10.1016/S1474-4422(17)30363-0
Eculizumab: a treatment option for myasthenia gravis?
Erratum in
-
Corrections.Lancet Neurol. 2018 Jan;17(1):26. doi: 10.1016/S1474-4422(17)30428-3. Epub 2017 Dec 16. Lancet Neurol. 2018. PMID: 29263000 No abstract available.
Comment on
-
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical